FDA Eliminates Biosimilar Testing Requirements, Slashing Development Costs
Understand FDA’s Oct. 2025 biosimilar framework that eliminates efficacy studies and cuts $100M+ costs via analytics, streamlines interchangeability for faster market entry.
Understand FDA’s Oct. 2025 biosimilar framework that eliminates efficacy studies and cuts $100M+ costs via analytics, streamlines interchangeability for faster market entry.